These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18709990)

  • 1. [False-positive reaction of urinary ketone bodies caused by bucillamine].
    Ogasawara H; Hayashi K; Toi H; Hagihara M; Tohda S; Miyasaka N; Tojo N
    Rinsho Byori; 2008 Jul; 56(7):584-8. PubMed ID: 18709990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical course of bucillamine-induced nephropathy in patients with rheumatoid arthritis.
    Obayashi M; Uzu T; Harada T; Yamato M; Takahara K; Yamauchi A
    Clin Exp Nephrol; 2003 Dec; 7(4):275-8. PubMed ID: 14712356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lung injury associated with bucillamine therapy].
    Negishi M; Kaga S; Kasama T; Hashimoto M; Fukushima T; Yamagata N; Tabata M; Kobayashi K; Ide H; Takahashi T
    Ryumachi; 1992 Apr; 32(2):135-9. PubMed ID: 1595005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A case of rheumatoid arthritis associated with agranulocytosis during bucillamine treatment].
    Negishi M; Yamazaki J; Hosaka M; Iwabuchi H; Matsuda A; Kanemitsu H; Hiramatsu K; Kaga S; Hashimoto M; Kasama T
    Ryumachi; 1994 Jun; 34(3):651-5. PubMed ID: 8052932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study.
    Suda A; Nagaoka S; Ohono S; Ideguchi H; Soga T; Ishigatsubo Y
    Mod Rheumatol; 2008; 18(6):609-14. PubMed ID: 18682889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bucillamine-associated membranous nephropathy in a patient with rheumatoid arthritis].
    Kawano M; Nomura H; Iwainaka Y; Nakashima A; Koni I; Tofuku Y; Takeda R
    Nihon Jinzo Gakkai Shi; 1990 Jul; 32(7):817-21. PubMed ID: 2273598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of rheumatoid arthritis developing pemphigus-like skin lesion during treatment with bucillamine].
    Amasaki Y; Sagawa A; Atsumi T; Jodo S; Nakabayashi T; Watanabe I; Mukai M; Fujisaku A; Nakagawa S; Kobayashi H
    Ryumachi; 1991 Oct; 31(5):528-34; discussion 531-3. PubMed ID: 1837388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunoglobulin and LST in RA patients treated with bucillamine].
    Hiramatsu K; Matsuzaki Y; Shiratori K; Miyakuni Y; Ando J; Inokuma S
    Ryumachi; 1995 Feb; 35(1):38-45. PubMed ID: 7732489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinicopathological evaluation and treatment of bucillamine induced membranous nephropathy].
    Kikuchi M; Saeki T; Ito S; In H; Saito T; Ueno M; Sato T; Suzuki S; Nakano M; Ozawa T
    Ryumachi; 1993 Jun; 33(3):215-22. PubMed ID: 8346463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunoglobulin decrease accompanying adverse reactions with bucillamine].
    Inokuma S; Sakata M; Ando J; Kobayashi S; Kiyosawa H; Nozawa F; Ito K
    Ryumachi; 1993 Aug; 33(4):316-24. PubMed ID: 8235913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of pulmonary infiltration with eosinophilia (PIE) syndrome induced by bucillamine treatment of rheumatoid arthritis].
    Kishimoto N; Fujii K
    Nihon Kokyuki Gakkai Zasshi; 2002 Apr; 40(4):321-5. PubMed ID: 12096503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten years results of bucillamine in the treatment of rheumatoid arthritis.
    Yokota N; Kuga Y; Kanazawa T; Morishita M; Tanida K; Itou K
    Mod Rheumatol; 2007; 17(1):33-6. PubMed ID: 17278020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bucillamine-induced dermatomyositis-like clinical features in a patient with rheumatoid arthritis].
    Takeda T; Shimizu Y; Takeuchi M; Hashimoto S; Nagai C; Uchiyama S; Iwata M
    Rinsho Shinkeigaku; 2005 Jan; 45(1):45-8. PubMed ID: 15715001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential influences of bucillamine and methotrexate on the generation of fibroblast-like cells from bone marrow CD34+ cells of rheumatoid arthritis patients.
    Hirohata S; Yanagida T; Tomita T; Yoshikawa H
    Int Immunopharmacol; 2009 Jan; 9(1):86-90. PubMed ID: 19000788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bucillamine-induced pemphigus vulgaris in a patient with rheumatoid arthritis and polymyositis overlap syndrome.
    Hur JW; Lee CW; Yoo DH
    J Korean Med Sci; 2006 Jun; 21(3):585-7. PubMed ID: 16778412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bucillamine-induced toxic epidermal necrolysis and fixed drug eruption.
    Izumi A; Katsumi S; Kobayashi N; Niizeki H; Asada H; Miyagawa S
    J Dermatol; 2005 May; 32(5):397-401. PubMed ID: 16043905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological findings of bucillamine-induced nephrotic syndrome in patients with rheumatoid arthritis.
    Yoshida A; Morozumi K; Suganuma T; Sugito K; Ikeda M; Oikawa T; Fujinami T; Takeda A; Koyama K
    Am J Nephrol; 1991; 11(4):284-8. PubMed ID: 1799186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison between bucillamine and D-penicillamine in the treatment of rheumatoid arthritis.
    Kim HA; Song YW
    Rheumatol Int; 1997; 17(1):5-9. PubMed ID: 9194208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of red amsler grid screening in a rheumatology clinic.
    Pluenneke AC; Blomquist PH
    J Rheumatol; 2004 Sep; 31(9):1754-5. PubMed ID: 15338495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine-derived 4-hydroxyphenylpyruvate reacts with ketone test fields of 3 commercially available urine dipsticks.
    Cartwright J; Green RM
    Vet Clin Pathol; 2010 Sep; 39(3):354-7. PubMed ID: 20487432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.